Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018 series compound segment supplier	Dec. 31, 2017	Jan. 01, 2019 USD ($)	Aug. 31, 2012 USD ($)
Accounting Policies [Line Items]
Number of series of selective cortisol modulators | series	3
Number of compounds | compound	500
Number of manufacturers | supplier	1
Cumulative payments to be made under financing agreement				$ 45.0
Number of operating segments | segment	1
Sales Revenue, Net | Customer Concentration Risk
Accounting Policies [Line Items]
Percentage of sales to one specialty distributor, less than	1.00%	1.00%
Financing Agreement with Biopharma
Accounting Policies [Line Items]
Payments as a percentage of quarterly sales				20.00%
Minimum | Scenario, Forecast | Accounting Standards Update 2016-02
Accounting Policies [Line Items]
Right-of-use asset			$ 1.5
Operating lease liability			1.5
Maximum | Scenario, Forecast | Accounting Standards Update 2016-02
Accounting Policies [Line Items]
Right-of-use asset			2.5
Operating lease liability			$ 2.5